Article metrics
PDF
Other content recommended for you
- CAR-T treatment for hematological malignancies
- Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- Unexpected neurologic complications following a novel lymphoma treatment ‘expected’ to give rise to neurologic toxicity
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
- Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
- Cardiotoxicities of novel cancer immunotherapies
- What is CAR T-cell therapy?